[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627104":3},{"organization":4,"outcomesModule":7,"designInfo":50,"detailedDescription":49,"studyPopulation":49,"armGroups":61,"interventions":73,"overallOfficials":49,"centralContacts":86,"locations":92,"responsibleParty":107,"collaborators":49,"id":109,"slug":49,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":49,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":116,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":49,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":49,"overallStatus":95,"whyStopped":49,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"Scholar Rock, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":33,"otherOutcomes":49},[9,13,15,17,19,21,23,25,27,29,31],{"measure":10,"description":11,"timeFrame":12},"Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participants","• Incidence of AEs","Up to 32 weeks",{"measure":10,"description":14,"timeFrame":12},"• Incidence of SAEs",{"measure":10,"description":16,"timeFrame":12},"Changes from baseline in clinical safety laboratory tests (serum chemistry)",{"measure":10,"description":18,"timeFrame":12},"Changes from baseline in clinical safety laboratory tests (hematology)",{"measure":10,"description":20,"timeFrame":12},"Changes from baseline in clinical safety laboratory tests (urinalysis)",{"measure":10,"description":22,"timeFrame":12},"Changes from baseline in clinical safety laboratory tests (coagulation assessments)",{"measure":10,"description":24,"timeFrame":12},"Changes from baseline in vital signs (heart rate) measured in bpm",{"measure":10,"description":26,"timeFrame":12},"Changes from baseline in vital signs (blood pressure) measured in mmHg",{"measure":10,"description":28,"timeFrame":12},"Changes from baseline in vital signs (respiratory rate) measured in rpm",{"measure":10,"description":30,"timeFrame":12},"Changes from baseline in vital signs (body temperature) measured in Celsius",{"measure":10,"description":32,"timeFrame":12},"Changes from baseline in ECG measurements",[34,37,39,41,43,46],{"measure":35,"description":36,"timeFrame":12},"Evaluate the PK of single and multiple SRK-439 SC dose administration in healthy adult participants","• Maximum observed serum concentration \\[Cmax\\]",{"measure":35,"description":38,"timeFrame":12},"• Time to maximum observed concentration in serum \\[Tmax\\]",{"measure":35,"description":40,"timeFrame":12},"• Area under the serum concentration-time curve \\[AUC\\]",{"measure":35,"description":42,"timeFrame":12},"• Terminal elimination half-life in serum \\[t1\u002F2\\]",{"measure":44,"description":45,"timeFrame":12},"Evaluate the PD of single and multiple SRK-439 SC dose administration in healthy adult participants","Serum concentrations of total latent myostatin and changes over time",{"measure":47,"description":48,"timeFrame":12},"Evaluate the immunogenicity of single and multiple SRK-439 SC dose administration in healthy adult participants","Incidence of ADAs against SRK-439 in serum",null,{"allocation":51,"interventionModel":52,"interventionModelDescription":49,"primaryPurpose":53,"observationalModel":49,"timePerspective":49,"maskingInfo":54},"RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":55,"maskingDescription":49,"whoMasked":56},"QUADRUPLE",[57,58,59,60],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[62,69],{"label":63,"type":64,"description":65,"interventionNames":66},"Part A","EXPERIMENTAL","Participants will be treated with a single dose of SRK-439 or matching placebo.",[67,68],"Drug: Placebo","Drug: SRK-439",{"label":70,"type":64,"description":71,"interventionNames":72},"Part B","Participants will be treated with multiple doses of SRK-439 or matching placebo.",[67,68],[74,79,83],{"type":75,"name":76,"description":77,"armGroupLabels":78,"otherNames":49},"DRUG","Placebo","Matching placebo to SRK-439, subcutaneous administration",[63,70],{"type":75,"name":80,"description":81,"armGroupLabels":82,"otherNames":49},"SRK-439","Single ascending dose, subcutaneous administration",[63],{"type":75,"name":80,"description":84,"armGroupLabels":85,"otherNames":49},"Multiple ascending dose, subcutaneous administration",[70],[87],{"name":88,"role":89,"phone":90,"phoneExt":49,"email":91},"Scholar Rock, Inc. Clinical Trials Administration","CONTACT","857-259-3860","MedicalInformation@scholarrock.com",[93],{"facility":94,"status":95,"city":96,"state":97,"zip":98,"country":99,"countryCode":100,"cosmosGeoPoint":101,"geoPoint":106,"contacts":49},"Medpace CPU","RECRUITING","Cincinnati","Ohio","45227","United States","US",{"type":102,"coordinates":103},"Point",[104,105],-84.51439,39.12711,{"lat":105,"lon":104},{"type":108,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100627104",false,"NCT07444294","A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults","A Phase 1 Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRK-439 in Healthy Adults","Key Inclusion Criteria:\n\n1. Male or female participants, ≥18 to ≤55 years of age, at the time of informed consent\n2. BMI of ≥18 kg\u002Fm2 to ≤35 kg\u002Fm2 (inclusive) at screening\n\nExclusion Criteria:\n\n1. Previous treatment with SRK-439 or apitegromab, or with other anti-myostatin therapies, including ACTR antagonists.\n2. History of immunosuppressive, chemotherapeutic, or radiation treatment within 12 months prior to screening.\n3. Current or prior use of anabolic steroids, growth hormones, or other substances with known effects on muscle.\n4. Use of therapies with potentially significant muscle effects (eg, insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form within 3 months prior to screening or during the study.\n5. Any history of exposure to a mAb or Fc domain-bearing recombinant protein within 5 years prior to screening with any prior history of hypersensitivity reactions from exposure\n6. Treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic within 3 months or 5 half-lives, whichever is longer, prior to screening.",true,"ALL","18 Years","55 Years",{"count":120,"type":121},76,"ESTIMATED","INTERVENTIONAL",[124],"PHASE1","A phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SRK-439 in healthy adults",[127],"Healthy","2026-02-24",{"date":130,"type":131},"2026-03-02","ACTUAL",{"date":133,"type":131},"2025-11-21",{"date":135,"type":121},"2027-06-09",{"name":5,"class":6},1]